TY - JOUR T1 - Review: paroxetine and placebo do not differ for treatment discontinuation in major depression JF - Evidence Based Medicine JO - Evid Based Med SP - 110 LP - 110 DO - 10.1136/ebm.13.4.110 VL - 13 IS - 4 A2 - , Y1 - 2008/08/01 UR - http://ebm.bmj.com/content/13/4/110.abstract N2 - C BarbuiDr C Barbui, University of Verona, Verona, Italy; corrado.barbui@univr.itIn participants with major depression, what is the effectiveness and acceptability of paroxetine?Included studies compared any flexible- or fixed-dose (⩾20 mg/d) regimen of any pharmaceutical form of paroxetine with placebo in participants ⩾18 years of age with major depression. Outcomes included treatment discontinuation, depression, <50% improvement in symptoms, adverse events, and suicidal tendencies.Medline; EMBASE/Excerpta Medica; Cochrane Collaboration Depression, Anxiety, and Neurosis Controlled Trials Register; Cochrane Central Register of Controlled Trials; and Glaxo-SmithKline Clinical Trial Register (all to December 2006) were searched for published and unpublished randomised placebo controlled trials (RCTs). 29 published RCTs and 11 unpublished RCTs (n = 6391) were included in … ER -